These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3580303)

  • 1. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs.
    Littlewood JD; Dawes J; Smith JK; Feldman PA; Haddon ME; McQuillan TA; Foster PR; Ferguson J; Prowse CV
    Br J Haematol; 1987 Apr; 65(4):463-8. PubMed ID: 3580303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
    Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
    Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombogenicity of a factor IX concentrate quantitated in a canine model.
    MacGregor IR; Ferguson JF; Dawes J; McLaughlin L; Prowse CV
    Blood Coagul Fibrinolysis; 1990; 1(1):23-30. PubMed ID: 2102787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro spontaneous thrombin generation in human factor-IX concentrates.
    Sas G; Owens RE; Smith JK; Middleton S; Cash JD
    Br J Haematol; 1975 Sep; 31(1):25-35. PubMed ID: 1212434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
    Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
    Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.
    Hampton KK; Makris M; Kitchen S; Preston FE
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):637-41. PubMed ID: 1782333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model.
    Harrison J; Abildgaard C; Lazerson J; Culbertson R; Anderson G
    Thromb Res; 1985 Apr; 38(2):173-88. PubMed ID: 4002204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
    Smith KJ
    Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated clotting factors in factor IX concentrates.
    Hultin MB
    Blood; 1979 Nov; 54(5):1028-38. PubMed ID: 497395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1976 Apr; 35(2):386-95. PubMed ID: 989639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human factor IX in animals: kinetics from isolated, radiolabelled protein and platelet destruction following crude concentrate infusions.
    Thompson AR; Forrey AW; Gentry PA; Smith KJ; Harker LA
    Br J Haematol; 1980 Jun; 45(2):329-42. PubMed ID: 7437328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H
    Thromb Res; 1982 Apr; 26(1):21-9. PubMed ID: 6980497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
    Hasan S; Abuelkasem E; Williams B; Henderson R; Mazzeffi MA; Tanaka KA
    Br J Anaesth; 2018 Oct; 121(4):936-943. PubMed ID: 30236256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.